Claims for Patent: 7,141,581

Summary for Patent: 7,141,581

Title:	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract:	Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s):	Bender; Steven (Oceanside, CA), Hu-Lowe; Dana (Encinitas, CA), Shalinsky; David Ray (San Diego, CA)
Assignee:	Agouron Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	10/639,890
Patent Claims:	1. A method of treating a hyperproliferative disorder in a mammal, the method comprising administering to said mammal a therapeutically effective amount of a composition comprising a compound of formula I: ##STR00023## wherein: R.sup.1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH.dbd.CH--R.sup.3 or CH.dbd.N--R.sup.3 where R.sup.3 is a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R.sup.2 is a substituted or unsubstituted aryl, heteroaryl, or Y--X, where Y is O, S, C.dbd.CH.sub.2, C.dbd.O, S.dbd.O, SO.sub.2, alkylidene, NH, or N--(C.sub.1 C.sub.8 alkyl), and X is substituted or unsubstituted Ar, heteroaryl, NH-(alkyl), NH-(cycloalkyl), NH-(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH-(alkoxyl), or NH-(dialkylamide); or pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein said hyperproliferative disorder is cancer. 3. The method of claim 2, wherein the cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, and combinations thereof. 4. The method of claim 1, wherein said hyperproliferative disorder is a noncancerous hyperproliferative disorder. 5. The method of claim 4, wherein said noncancerous hyperproliferative disorder is a benign hyperplasia of the skin or prostate. 6. The method of claim 1, further comprising administering to the mammal an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens, and mixtures thereof. 7. A method for treating a disease related to vasculogenesis or angiogenesis in a mammal, the method comprising administering to said mammal a therapeutically effective amount of a composition comprising a compound of formula I: ##STR00024## wherein: R.sup.1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH.dbd.CH--R.sup.3 or CH.dbd.N--R.sup.3 where R.sup.3 is a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R.sup.2 is a substituted or unsubstituted aryl, heteroaryl, or Y--X, where Y is O, S, C.dbd.CH.sub.2, C.dbd.O, S.dbd.O, SO.sub.2, alkylidene, NH, or N--(C.sub.1 C.sub.8 alkyl), and X is substituted or unsubstituted Ar, heteroaryl, NH-(alkyl), NH-(cycloalkyl), NH-(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH-(alkoxyl), or NH--(dialkylamide); or pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 8. The method of claim 7, wherein said disease is selected from the group consisting of tumor angiogenesis, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer. 9. The method of claim 7, further comprising administering to the mammal a therapeutically effective amount of an anti-hypertensive agent. 10. A method according to claim 1, wherein said compound of formula I is selected from the group consisting of: ##STR00025## ##STR00026## 11. A method according to claim 7, wherein said compound of formula I is selected from the group consisting of: ##STR00027## ##STR00028##